.png)
The clinical trial, jointly funded in the Strituvad project by the EC-Horizon 2020 programme and the Department of Biotechnology, Government of India, is expected to start this August 2021 with the recruitment of the first patients.
At the end of June the STRITUVAD project have successfully concluded the regulatory path to start the phase IIb clinical study with title “Double-Blind, Randomized, Placebo-Controlled Phase IIb Clinical Trial to Investigate the Efficacy of RUTI® Therapeutic Vaccination as adjuvant of Tuberculosis chemotherapy”.
The project, which is funded jointly by the European Commission and the Department of Biotechnology of India, has finally collected all the necessary approvals to start the clinical trial.
The last one was expected from the Central Drugs Laboratory of the Indian Government, which has tested the batch of RUTI vaccine recently sent to the Indian facilities and meant for the phase II clinical trial.
